Protagonist Therapeutics Inc (NASDAQ:PTGX) Receives $19.80 Average Price Target from Brokerages

Shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) have been assigned a consensus rating of “Buy” from the eight ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $19.80.

A number of research firms have recently weighed in on PTGX. Nomura restated a “buy” rating and issued a $29.00 price target on shares of Protagonist Therapeutics in a research note on Sunday, August 11th. Svb Leerink reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research report on Tuesday, August 13th. ValuEngine downgraded shares of Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 30th. BidaskClub downgraded shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 8th. Finally, HC Wainwright set a $23.00 target price on shares of Protagonist Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 2nd.

PTGX stock opened at $11.59 on Wednesday. The company has a quick ratio of 4.12, a current ratio of 4.12 and a debt-to-equity ratio of 0.08. Protagonist Therapeutics has a 12 month low of $5.49 and a 12 month high of $16.67. The firm has a market cap of $317.20 million, a P/E ratio of -6.66 and a beta of 1.72. The company’s 50-day moving average price is $13.25 and its two-hundred day moving average price is $11.84.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Wednesday, August 7th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.90). Protagonist Therapeutics had a negative net margin of 209.02% and a negative return on equity of 62.50%. The firm had revenue of ($8.19) million during the quarter, compared to the consensus estimate of $10.77 million. Equities analysts predict that Protagonist Therapeutics will post -3.24 EPS for the current year.

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 10,792 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $8.85, for a total transaction of $95,509.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Y. Liu sold 3,395 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $8.85, for a total transaction of $30,045.75. The disclosure for this sale can be found here. Insiders own 14.20% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC boosted its holdings in Protagonist Therapeutics by 12.7% during the 2nd quarter. Citadel Advisors LLC now owns 409,847 shares of the company’s stock worth $4,963,000 after acquiring an additional 46,120 shares during the last quarter. Allianz Asset Management GmbH boosted its holdings in Protagonist Therapeutics by 61.3% during the 2nd quarter. Allianz Asset Management GmbH now owns 124,090 shares of the company’s stock worth $1,503,000 after acquiring an additional 47,175 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Protagonist Therapeutics by 99.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 558,729 shares of the company’s stock worth $6,693,000 after acquiring an additional 278,066 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Protagonist Therapeutics by 63.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 19,486 shares of the company’s stock worth $236,000 after acquiring an additional 7,586 shares during the last quarter. Finally, VHCP Management II LLC boosted its holdings in Protagonist Therapeutics by 57.3% during the 2nd quarter. VHCP Management II LLC now owns 426,781 shares of the company’s stock worth $5,168,000 after acquiring an additional 155,404 shares during the last quarter. Institutional investors and hedge funds own 73.41% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Read More: Is the QQQ ETF safe?

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News